Results 21 to 30 of about 15,495 (255)

Characterization of qnrB-carrying plasmids from ESBL- and non-ESBL-producing Escherichia coli

open access: yesBMC Genomics, 2022
Abstract Background Escherichia coli carrying clinically important antimicrobial resistances [i.e., against extended-spectrum-beta-lactamases (ESBL)] are of high concern for human health and are increasingly detected worldwide.
Juraschek, Katharina   +6 more
openaire   +3 more sources

Prevalence of multiresistant gram-negative organisms in a tertiary hospital in Mwanza, Tanzania. [PDF]

open access: yes, 2009
\ud Antimicrobial resistance is fast becoming a global concern with rapid increases in multidrug-resistant Gram negative organisms. The prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates increases the burden on implementing
Kamugisha, Erasmus   +19 more
core   +1 more source

Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms [PDF]

open access: yesClinical Microbiology and Infection, 2001
The rapid and irrepressible increase in antimicrobial resistance of pathogenic bacteria that has been observed over the last two decades is widely accepted to be one of the major problems of human medicine today. Several aspects of this situation are especially worrying.
openaire   +2 more sources

Molecular Identification of TEM and SHV Genes in Extended Spectrum Beta-lactamase Producing Escherichia coli and Klebsiellae pneumoniae Isolates in a Tertiary Care Hospital, Bangladesh

open access: yesJournal of Pure and Applied Microbiology, 2017
Extended spectrum b-lactamases (ESBLs) are enzymes encoded by mutation of a class of genes such as TEM, SHV, OXA and CTX etc. in gram negative Enterobacteriaceae.
Md. Hasanul Karim   +2 more
doaj   +1 more source

Global evaluation of the antibacterial activity of Ceftolozane/Tazobactam against ESBLs-producing and : a systematic review and meta-analysis

open access: yesTherapeutic Advances in Infectious Disease, 2023
Background: Ceftolozane/Tazobactam is a β-lactam/β-lactamase inhibitor combination with a high range of efficacy and broad-spectrum action against multidrug-resistant bacterial strains. Objectives: The present study aimed to analyze the in vitro activity
Marzieh Rahim Khorasani   +3 more
doaj   +1 more source

MDR, ESBLs and carbapenemase enzyme production patterns of Gram-negative isolates.

open access: yes, 2022
MDR, ESBLs and carbapenemase enzyme production patterns of Gram-negative isolates.
Dagimawie Tadesse (276579)   +3 more
core   +1 more source

Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases [PDF]

open access: yes, 2021
Background: ESBL- and carbapenemase-producing Pseudomonas aeruginosa are prevalent in, for example, the Middle East, Eastern Europe and Latin America, though rarer elsewhere. Because P. aeruginosa readily mutate to become carbapenem resistant via loss of
Vickers, Anna   +4 more
core   +1 more source

Characterisation of Extended-Spectrum β-Lactamases among Multidrug Resistant Enterobacteriaceae from Sudan

open access: yesJournal of Pure and Applied Microbiology, 2019
The aim of the present study was to characterize extended-spectrum β-lactamase (ESBLs) genes in multidrug resistant enterobacterial pathogens as well as commensal isolates from the Sudan during the period 2003 to 2007.
Malik I.A, Elhag K.M.
doaj   +1 more source

High level detection of extended spectrum beta-lactamase gene encoding Enterobacteriaceae in public toilets in Abeokuta, Nigeria

open access: yesCeylon Journal of Science, 2020
Increasing reports of the pandemic nature of extended spectrum β-lactamase (ESBL) producing bacteria in clinical infections called for more surveillance to identify possible sources of infection.
S.A. Balogun   +3 more
doaj   +1 more source

Initial Screening Tests for ESBLs.

open access: yes, 2015
For K. oxytoca, the breakpoints of the CPD, CRO, and ATM zones are ≤17 mm, ≤25 mm, and ≤27 mm, respectively. According to the CLSI, “Zones above may indicate ESBL production.”Abbreviations: ESBL, extended-spectrum β-lactamase; CPD, cefpodoxime; ATM ...
Yoshichika Arakawa (183806)   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy